This study involves taking a study drug called
ramucirumab. The overall goal of this study is to see how effective ramucirumab
is when given in combination with gemcitabine and docetaxel in children
and young adults with synovial sarcoma.
This study involves taking a study drug called ramucirumab.
The overall goal of this study is to see how effective ramucirumab is when
given in combination with cyclophosphamide and vinorelbine in children and
young adults with desmoplastic small round cell tumor (DSRCT).
This study involves taking a study drug called
bosutinib. The overall goals of this study are to find the best
dose of bosutinib that we can give safely, and to find out what effects, good
and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).
This study involves taking a study drug called CUDC-907. CUDC-907 is an oral drug that blocks certain
proteins in tumor cells; these proteins may be important in the growth of some
cancers. The overall goals of this study are to evaluate the side effects and
benefits of CUDC-907 in patients with relapsed or treatment refractory solid
tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for
children and adolescents. This study
will also look at the levels of CUDC-907 in the blood over time after a dose.
CHOP, in collaboration with Onyx Therapeutics, Inc., is
conducting a study for children and young adults up to 21 years old, with relapsed
or refractory acute lymphoblastic leukemia. This clinical trial is adding the
study drug, Carfilzomib, to a standard relapse chemotherapy regimen. For more
information about this study, including specific eligibility criteria, please
visit clinicaltrials.gov and search for "NCT02303821". To hear more
about this and other available trails or get any questions answered please
contact our Cancer Intake Specialist by phone at 267-426-0762 or email Oncointake@email.chop.edu.
For patients (and parents of patients) that have been diagnosed with, pediatric
acute lymphoblastic leukemia (ALL), nausea and vomiting are among the most bothersome
symptoms during chemotherapy treatment.
The overall goal of this study is to find the best strategies used by parents
and patients for managing these symptoms when receiving maintenance therapy.
The purpose of this study is to find out if alpelisib (BYL719;
the “study drug”), is safe and effective (can help) people who have PIK3CA-related overgrowth spectrum (PROS) disease.
The purpose of this study
is to determine the highest safe dose of abemaciclib in patients with relapsed
or treatment refractory solid tumors given in combination with the chemotherapy
drugs, irinotecan and temozolomide (Part A) or in combination with just temozolomide
(Part B).
This study involves taking a study drug called ALRN-6924. ALRN-6924
is an investigational cancer treatment that activates p53, which suppresses the
growth of tumors by blocking proteins in the cell called MDM2 and MDMX that
inhibit p53 from doing its job. The overall goals of this
study are to evaluate the side effects and benefits of ALRN-6924 in patients
with relapsed or treatment refractory solid tumor or brain tumor, and to determine
the best dose of ALRN-6924 for children and adolescents. This study will also
look at how the body breaks down ALRN-6924 by measuring the amount of ALRN-6924
in the blood over time after a dose.
This study involves taking a study drug called
TAS-117. The overall goal of this study is to see if TAS-117 is a possible
treatment for advanced cancers with germline mutations in the PTEN gene.